Lead

On June 5, South Africa will begin rolling out lenacapavir (LEN), an HIV prevention injection taken only twice a year, in what health officials describe as one of the country's most significant prevention drives in decades. Health Minister Aaron Motsoaledi announced the launch during the department's budget vote, stating that the injection will initially be available at 360 government clinics in high-burden districts.

The injection offers six months of continuous protection per dose, providing an alternative to daily pills or bi-monthly injections. According to Motsoaledi, the rollout will prioritise adolescent girls and young women up to age 24, pregnant and breastfeeding mothers, female sex workers, men who have sex with men, transgender people, and injecting drug users.

The minister expressed confidence that South Africa could eliminate HIV/AIDS as a public health threat, citing the country's progress in increasing life expectancy, reducing maternal and under-5 mortality, and lowering TB incidence. However, the launch comes at a time when donor funding for HIV prevention is shrinking, raising questions about whether the new tool can reach those who need it most.

Coverage Comparison

Two reports from AllAfrica highlight both the promise and the challenges of the rollout. The first, based on the minister's budget vote speech, is largely optimistic, framing lenacapavir as a "game changer" and a "welcome relief" for patients. It emphasises South Africa's achievements in tackling HIV and quotes Motsoaledi's ambitious goals.

The second report adopts a more cautionary tone, focusing on the gap between the injection's potential and the realities of implementation. It warns that "funding cuts have weakened the very programmes needed to deliver the drug," and quotes experts who describe the situation as a "dangerous mistake." While the first report focuses on the government's message, the second draws attention to the systemic issues that could undermine the rollout.

Both sources agree on the basic facts of the launch date and the targeted groups, but they differ in emphasis: the first sees the launch as a milestone, the second as a test of political will and funding commitments.

Key Claims

  • Lenacapavir is administered via injection twice a year, offering six months of protection per dose, as reported by both AllAfrica articles.
  • The launch will take place on June 5 in Mpumalanga, with initial distribution to 360 health facilities, according to Health Minister Aaron Motsoaledi.
  • South Africa has increased life expectancy to 66.9 years by 2025, reduced maternal mortality to 89 deaths per 100,000 live births, reduced under-5 mortality to 27.7 per 1,000 live births, and reduced TB incidence to 4,217 per 100,000 population, as stated by the minister in the budget vote speech.
One report highlights that funding cuts have impacted HIV prevention programmes, with the Global Fund and Pepfar reducing their support. The same report claims that these funders have actually increased their commitment to provide enough LEN doses for three million people over the next three years, but that community programmes for high-risk groups have been "gutted" and Pepfar no longer tracks these groups. It also notes that the number of people starting HIV prevention medication has fallen by 41%, including among teenage girls and young women (15–24).

These claims come from a single report and have not been independently verified. Modelling studies cited in that report suggest South Africa needs between one and two million people to receive LEN each year to lower new infections, more than any other country.

Perspectives

Government and health officials view the rollout as a major achievement, citing strong political commitment and notable health gains. They argue that with continued effort, HIV/AIDS can be eliminated as a public health threat.

Community health experts and activists are more cautious, warning that funding cuts have already weakened the very programmes that help high-risk populations access prevention. They stress that LEN alone cannot stop the epidemic without strong investment in community outreach and trusted health workers.

Donor organisations (Global Fund, Pepfar) are reportedly increasing their commitment to providing LEN doses, but the broader trend of shrinking prevention budgets remains a concern. The tension between new tools and eroding infrastructure is central to the challenge ahead.